Monday watchlist today, June 01: Nifty volatility continues as pharma and metal indices signal short-term reversals; review your trading strategy…
Monday watchlist, May 24: FIIs spark fresh optimism with Friday longs; Private Banks set for a rally—track the momentum and…
Indian pharma may be entering a new era. Bernstein says the next winners may not come from vanilla generics but…
Nomura sees up to 26% upside in Cipla, Dr Reddy’s Lab, and Crompton Greaves—discover why these stocks are top picks…
Cipla surges 8% despite 55% profit drop as brokerages turn bullish—explore if this rally signals a buying opportunity!
Cipla Q4 profit plunges 55% to Rs 555 crore; company announces Rs 13 dividend. Learn more about Cipla’s financial results!
Top Indian firms pledge billions in pharma, manufacturing and energy, as both nations push to double bilateral trade to $500…
A look at some of the undervalued pharma stocks in India.
Government to hire consultant to study pharma, MedTech logistics, aiming to cut costs, fix cold-chain gaps and ease regulatory bottlenecks…
Bombay High Court rules that drug variants not listed in NLEM are exempt from price caps under DPCO 2013, offering…
Emkay Global sees a 29% upside for Granules India with strong US market gains—consider adding this high-conviction small-cap to your…
Sun Pharma may be the most exposed to US tariffs but a global buffer could quietly limit the real damage.
Sai Parenteral lists at a 2% premium in a weak market; check IPO performance.
The Confederation of Indian Industry (CII) has petitioned the Department of Pharmaceuticals for freight subsidies and drug pricing relaxations as…
Monday watchlist, March 30: Track Sun Pharma, HDFC Bank and ICICI as market volatility surges; review key stock setups and…
While NATHEALTH leaders highlight a $1 trillion opportunity in raising India’s Health-Adjusted Life Expectancy (HALE), the industry must first navigate…
Ozempic patent expiry has triggered a fresh pharma race in India. Sun Pharma, Cipla, and Dr Reddy’s are among 7…
A key US drug approval is putting this pharma stock back on the radar, with a global brokerage pointing to…